SEARCH

SEARCH BY CITATION

References

  • 1
    Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 26681.
  • 2
    Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 92: 48.
  • 3
    Christakos S, Dhawan P, Benn B, et al. Vitamin D: molecular mechanism of action. Ann N Y Acad Sci 2007; 1116: 3408.
  • 4
    DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: 1689S96.
  • 5
    Christakos S, Dhawan P, Peng X, et al. New insights into the function and regulation of vitamin D target proteins. J Steroid Biochem Mol Biol 2007; 103: 40510.
  • 6
    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S88.
  • 7
    Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79: 36271.
  • 8
    Horvath E, Lakatos P, Balla B, Kosa J, Kovalszky I, Szalay F. Remarkable increase in CYP24A1 mRNA level after 1,25-dihydroxyvitamin D3 treatment of hepatocellular carcinoma cell lines. J Hepatol 2011; 54: S94.
  • 9
    Bitetto D, Fabris C, Falleti E, et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 41744.
  • 10
    Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 51320.
  • 11
    Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 115867.
  • 12
    Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 26248.
  • 13
    Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010; 4: 63440.
  • 14
    Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16: 10227.
  • 15
    Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89: 432530.
  • 16
    Lange C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 88793.
  • 17
    Kastens S, Grüngreiff K, Terkamp C, et al. Serum zinc but not serum vitamin D levels are associated with disease severity and treatment response in chronic hepatitis C virus infection. J Hepatol 2011; 54: S458.
  • 18
    Stauber R, Scherzer T, Putz-Bankuti C, et al. Baseline vitamin D levels do not influence SVR in patients with chronic HCV genotype 1 or 4 infection undergoing peginterferon/ribavirin treatment. J Hepatol 2011; 54: S468.
  • 19
    Choudhary N, Tomar M, Chawla YK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci 2011; 56: 33237.
  • 20
    Nseir W., Gali M, Mouch SA, Djibre A, Nassar F, Assy N. Baseline serum HDL and vitamin D levels are strongly associated with SVR in chronic hepatitis C naïve genotype 1 patients. J Hepatol 2011; 54: S450.
  • 21
    Mouch S, Assy N. Vitamin D supplementation improves viral response in chronic hepatitis C genotype 2/3 patients treated with Peg-interferon alpha and ribavirin. Hepatology 2010; 52: 708A.
  • 22
    Bitetto D, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 111826.
  • 23
    Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 75661.
  • 24
    Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 4350.
  • 25
    George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009; 15: 351622.
  • 26
    Nusbaum J, Wright HC, Smirniotopoulos J, et al. Vitamin D deficiency in cirrhosis relates to severity and not etiology of liver disease. Hepatology 2011; 54(Suppl. 4): 1253A.
  • 27
    Solis-Herruzo JA, Castellano G, Fernandez I, et al. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 8127.
  • 28
    Carey EJ, Balan V, Kremers WK, et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003; 9: 116673.
  • 29
    Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 18437.
  • 30
    Yenice N, Gumrah M, Mehtap O, et al. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol 2006; 17: 2606.
  • 31
    Hofmann WP, Kronenberger B, Bojunga J, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008; 15: 7906.
  • 32
    Nanda KS, Ryan EJ, Murray BF, et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 2009; 7: 8949.
  • 33
    Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 6959.
  • 34
    Petta S, Ferraro D, Scazzone C, et al. Low vitamin D serum levels is related to rapid early and sustained virological response to IFN-based therapy in genotype 1 chronic hepatitis C. J Hepatol 2011; 54: S468.
  • 35
    Jazwinski A, Clark PJ, Tillmann HL, Muir AJ. Vitamin D and treatment response in African American patients with HCV genotype 1. Hepatology 2011; 54(Suppl. 4): 853A.
  • 36
    Almerighi C, Franceschelli A, Francioso S, et al. High dose vitamin D supplementation in genotype 1 chronic hepatitis C patients with advanced fibrosis/compensated cirrhosis non responders to standard therapy: results of the HEP-D3 study. Hepatology 2011; 54(Suppl. 4): 857A.
  • 37
    Soumekh A, Bichoupan K, Constable K, et al. Two novel findings about interferon/ribavirin treatment serum calcium falls and 25- hydroxyvitamin D increases. Hepatology 2011; 54(Suppl. 4): 856A.
  • 38
    Reiberger T, Payer BA, Obermayer-Pietsch B, Rieger A, Peck-Radosavljevic M. 25-OH-Vitamin D levels are associated with early viral kinetics and sustained virologic response in patients with HCV-HIV co-infection. Hepatology 2011; 54(Suppl. 4): 1191A.
  • 39
    Monegal A, Navasa M, Guanabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 14854.
  • 40
    Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zugel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 2010; 118: 14250.
  • 41
    Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 78796.
  • 42
    Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 2006; 21(Suppl. 3): S88S91.
  • 43
    Doron S, Amer J, Abu-Tair L, Mahamid M, Abu-Mouch S, Safadi R. Anti-fibrotic immune modulation effects of 25-OH vitamin D in HCV and mice fibrosis model. J Hepatol 2011; 54: S68.
  • 44
    Shen L. Vitamin D controls T cell activation: implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C. Hepatology 2010; 52: 1864.
  • 45
    Nakano T, Cheng YF, Lai CY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011; 55: 41525.
  • 46
    Suneetha PV, Sarin SK, Goyal A, Kumar GT, Shukla DK, Hissar S. Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol 2006; 44: 85663.
  • 47
    Assy N, Djibre A, Tzuker M, et al. Vitamin D supplement prevent myalgia and elevation of CPK in chronic hepatitis B patients treated with telbivudine. J Hepatol 2011; 54: S283.
  • 48
    Ji HF. Vitamin D levels may explain the racial differences in response rates to antiviral therapy of chronic hepatitis C. Hepatology 2011; 54: 1489.
  • 49
    Segal E, Baruch Y, Kramsky R, Raz B, Ish-Shalom S. Vitamin D deficiency in liver transplant patients in Israel. Transplant Proc 2001; 33: 29556.
  • 50
    Premaor MO, Alves GV, Crossetti LB, Furlanetto TW. Hyperparathyroidism secondary to hypovitaminosis D in hypoalbuminemic is less intense than in normoalbuminemic patients: a prevalence study in medical inpatients in southern Brazil. Endocrine 2004; 24: 4753.
  • 51
    Bitetto D, Fabris C, Falleti E, Toniutto P. Vitamin D deficiency and HCV chronic infection: what comes first? J Hepatol 2011; 55: 9445.
  • 52
    Binkley N. Vitamin D: clinical measurement and use. J Musculoskelet Neuronal Interact 2006; 6: 33840.
  • 53
    Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011; 55: 2735.